Evidence map›Paper›PMID 40765716›Full record

ArticleNAM journal2025

Complement-ARIE: Catalyzing the Development and Adoption of New Approach Methodologies.

Kristifor Sunderic, Andrew M Wright, Nicole Kleinstreuer, Victoria Ledbetter, Katelynn A Milora, Christine Happel, Daniel Shaughnessy, Chariz P Johnstone, Daniel Anthony Casco, Nikeya Macioce and 4 more

Abstract read
In one paragraph

Article in NAM journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. New approach methodologies in neurotherapeutics development.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kristifor SundericNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.
Andrew M WrightOffice of the Director, National Institutes of Health, Bethesda, MD 20892, USA.
Nicole KleinstreuerOffice of the Director, National Institutes of Health, Bethesda, MD 20892, USA.
Victoria LedbetterNational Institute of Environmental Health Science, National Institutes of Health, Bethesda, MD 20892, USA.
Katelynn A MiloraOffice of the Director, National Institutes of Health, Bethesda, MD 20892, USA.
Christine HappelNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.
Daniel ShaughnessyNational Institute of Environmental Health Science, National Institutes of Health, Bethesda, MD 20892, USA.
Chariz P JohnstoneNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.
Daniel Anthony CascoOffice of the Director, National Institutes of Health, Bethesda, MD 20892, USA.
Nikeya MacioceOffice of the Director, National Institutes of Health, Bethesda, MD 20892, USA.
Jacqui MarzecNational Institute of Environmental Health Science, National Institutes of Health, Bethesda, MD 20892, USA.
Kristin KanoOffice of the Director, National Institutes of Health, Bethesda, MD 20892, USA.
Margaret J OchocinskaOffice of the Director, National Institutes of Health, Bethesda, MD 20892, USA.
Danilo A TagleNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-0071-4612

Funding

Intramural NIH HHS Z99 TR999999
6 · The paper itself

Abstract

New approach methodologies (NAMs) are proving to be invaluable tools in basic and clinical research to better understand human health and disease, elucidate mechanisms, and study the efficacy and toxicity of novel therapeutics that can improve upon and complement animal-based methodologies. Over the last 15 years, the National Institutes of Health (NIH) has increased investment in NAMs, including in chemico, in silico, and in vitro approaches, such as cell-free assay systems, digital twins, and microphysiological systems (MPS). To further catalyze and innovate the use of NAMs, the NIH Common Fund has initiated a new program, Complement Animal Research In Experimentation (Complement-ARIE), which aims to pioneer the development, standardization, validation, and regulatory use of combinatorial NAMs that will more accurately model human biology and disease states. This program specifically aims to 1) better model human health and disease differences in outcomes across populations, 2) develop NAMs that can provide insights into specific biological processes or disease states, 3) validate mature NAMs to support regulatory use and standardization, and 4) complement traditional animal models to make research more efficient and effective. To inform the implementation of Complement-ARIE, the NIH organized strategic planning activities including an inter-agency retreat, public listening sessions, scientific literature landscape analysis, and a challenge prize. Here we discuss the goals and findings of these activities, and how these results helped identify and address scientific and operational opportunities and roadblocks for implementation of the program towards broader acceptance and impact of NAMs. We anticipate these new methods and approaches could transform the way we do basic, translational, and clinical sciences.

Indexed as

Complement Animal Research In Experimentation, Complement-ARIEin chemicoin silicoin vitromicrophysiological systems, MPSNational Institutes of Health, NIHNew approach methodologies, novel alternative methods, NAMs

Identifiers

PMID40765716
PMCPMC12320934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.